Evidence map›Paper›PMID 33329522›Full record

ArticleFrontiers in immunology2020

The Neoantigen Landscape of Mycosis Fungoides.

Arunima Sivanand, Dylan Hennessey, Aishwarya Iyer, Sandra O'Keefe, Philip Surmanowicz, Gauravi Vaid, Zixuan Xiao, Robert Gniadecki

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. TOX Expression in Mycosis Fungoides and Sezary Syndrome.Diagnostics (Basel, Switzerland) · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Arunima SivanandDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Dylan HennesseyDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Aishwarya IyerDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Sandra O'KeefeDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Philip SurmanowiczDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Gauravi VaidDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Zixuan XiaoDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Robert GniadeckiDivision of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CA

Funding

CIHR
6 · The paper itself

Abstract

Background: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, for which there is no cure. Immune checkpoint inhibitors have been tried in MF but the results have been inconsistent. To gain insight into the immunogenicity of MF we characterized the neoantigen landscape of this lymphoma, focusing on the known predictors of responses to immunotherapy: the quantity, HLA-binding strength and subclonality of neoantigens. Methods: Whole exome and whole transcriptome sequences were obtained from 24 MF samples (16 plaques, 8 tumors) from 13 patients. Bioinformatic pipelines (Mutect2, OptiType, MuPeXi) were used for mutation calling, HLA typing, and neoantigen prediction. PhyloWGS was used to subdivide malignant cells into stem and clades, to which neoantigens were matched to determine their clonality. Results: MF has a high mutational load (median 3,217 non synonymous mutations), resulting in a significant number of total neoantigens (median 1,309 per sample) and high-affinity neoantigens (median 328). In stage I disease most neoantigens were clonal but with stage progression, 75% of lesions had >50% subclonal antigens and 53% lesions had CSiN scores <1. There was very little overlap in neoantigens across patients or between different lesions on the same patient, indicating a high degree of heterogeneity. Conclusions: The neoantigen landscape of MF is characterized by high neoantigen load and significant subclonality which could indicate potential challenges for immunotherapy in patients with advanced-stage disease.

Indexed as

Antigens, NeoplasmBiomarkers, TumorClonal EvolutionComputational BiologyDisease ManagementDisease ProgressionDisease SusceptibilityExome SequencingFemaleGene Expression ProfilingHumansMaleMutationMycosis FungoidesNeoplasm StagingPeptidesAntigens, NeoplasmBiomarkers, TumorPeptidescutaneous T-cell lymphomaimmunogenicityimmunotherapymycosis fungoidesneoantigen

Identifiers

PMID33329522
PMCPMC7719792
OpenAlexW3108807472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.